Indiana University School Of Medicine

Cumberland Pharmaceuticals' Phase 2 FIGHT DMD trial demonstrated that high-dose ifetroban treatment resulted in a significant 5.4% improvement in left ventricular ejection fraction compared to control groups.

New research presented at ATS 2025 reveals that sleep patterns in ICU patients may serve as important biomarkers for predicting patient outcomes, with atypical N3 sleep linked to longer ICU stays.

A pilot study of 15 women demonstrated that once-weekly oral secnidazole granules reduced bacterial vaginosis recurrence to 20% over 28 weeks, compared to CDC-recommended treatments with 35-70% recurrence rates.

Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment.

GLP-1 receptor agonist use has increased dramatically among type 1 diabetes patients, with prescriptions rising from 4% to 33% in severely obese adults over the past decade.

Retroperitoneal lymph node dissection (RPLND) is emerging as an effective treatment for early-stage II seminoma, potentially reducing reliance on chemotherapy.